MedTrace Logo

Direct Statin Comparison of LDL-C Values: an Evaluation of Rosuvastatin Therapy

NCT00239330 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 824

Last updated 2010-11-19

No results posted yet for this study

Summary

The primary objective of the study is to compare the efficacy of rosuvastatin 10 mg with atorvastatin 10 mg by assessment of the percentage of subjects who reach EAS LDL-C target goals after 12 weeks of therapy.

Conditions

  • Hypercholesteremia

Interventions

DRUG

Rosuvastatin

DRUG

Atorvastatin

Sponsors & Collaborators

Principal Investigators

  • Guy Vandenhoven, MD · AstraZeneca NV/SA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2005-02-28
Completion
2005-02-28

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00239330 on ClinicalTrials.gov